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Background: There is evidence that proven pulmonary and meningeal cases of tuberculosis 
(TB) are associated with a worse outcome than presumed cases. 
 Aim: To determine if survival is comparable for definite versus probable TB pericarditis 
among patients treated for TB pericarditis at the Groote Schuur Hospital (GSH). 
Methods:  A retrospective cohort study was conducted on newly diagnosed TB pericarditis 
cases referred to the GSH for pericardiocentesis from January 2006 to December 2010. Based 
on a folder review, baseline characteristics and laboratory findings were collected, and 
patients assigned as definite or probable TB pericarditis. A definite diagnosis was one in 
which pericardial fluid or tissue tested positive for TB, whilst a probable diagnosis was based 
on negative microbiological findings in the presence of clinical and indirect laboratory 
findings. The probable group was further divided into those with proven TB in another part of 
the body (except the heart) and those with probable TB.  
Results: 192 patients that had a pericardiocentesis for suspected TB pericarditis were 
followed up for a median of 52.9 weeks (15.14 - 90.6). 93 (48.4%) of the patients had definite 
disease, 20 (10.4%) had probable disease with TB elsewhere and 79 (41.1%) had probable 
disease with no TB elsewhere; mortality was 19 (20.4%), 4 (20%) and 13 (16.5%), 
respectively over the follow-up period (p = 0.799).  The predictors of mortality were low 
diastolic blood pressure, presence of cardiac tamponade and older age. The overall incidence 
rate of recurrent pericardial effusion was 47.1 cases per 1000 person-years; of constrictive 
pericarditis was 132.2 cases per 1000 person-years and of pericardiectomy was 34.4 cases per 




Conclusions: The survival and outcome of definite and probable TB pericarditis are the 
same. With attention to clinical parameters on admission, it is possible to determine which 
patients need more clinical care. 
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PART A: PROTOCOL 
THE INVESTIGATION OF THE MANAGEMENT OF PERICARDITIS (IMPI) 
REGISTRY 
SURVIVAL AND OUTCOMES SUB-STUDY 
1.0 INTRODUCTION 
Tuberculosis (TB) continues to rank amongst the leading causes of preventable disease in the 
developing world. In 2010, there were approximately 8.5 to 9.2 million cases of TB, and 
between 1.2 and 1.5 million deaths worldwide - 59% of these cases occurred in South East 
Asia and 26% in Africa, with continuing increases because of the human immunodeficiency 
virus (HIV) pandemic. (1) 
The HIV pandemic has given rise to a changing epidemiology of TB and even more 
importantly, of extrapulmonary TB. In immunocompetent individuals, extrapulmonary TB 
constitutes between 15 to 20% of all TB cases, but this figure escalates to more than 50% in 
those who are HIV positive.(2) HIV infection is thus associated with a rising incidence of all 
forms of extrapulmonary TB, including TB pericarditis.(3)  
TB pericarditis carries a high mortality and morbidity, and it affects young people with a 
median age of 33 years. (4) If the condition accounts for 1 - 2% of all cases of TB, then about  
500,000 to 1,000,000 individuals will be affected with TB pericarditis over the next 5 years. 
(5-­‐7)  The high burden of disease is reflected by the fact that TB pericarditis accounts for about 
10% of patients hospitalized with heart failure in some parts of Africa(8). In one series from 
the Western Cape Province of South Africa, TB pericarditis was responsible for 70% of cases 
referred with large pericardial effusion (9).   In South Africa, at least half the patients with 




The diagnosis of definite/proven TB pericarditis rests on the finding of Mycobacterium 
tuberculosis (M. tuberculosis) in either pericardial fluid or tissue (6). The bacilli are 
demonstrated by staining and/or, positive culture in pericardial fluid, or the presence of 
caseating granulomata on histology of the pericardial tissue. Therefore, in order to prove TB 
pericarditis, pericardial fluid and/or tissue needs to be collected, usually via a diagnostic 
pericardiocentesis or pericardial biopsy. Generally M.tuberculosis yield in smears or in 
culture from body fluids, including pericardial fluid, is about 40-60% in endemic areas (7). To 
try and improve on this, molecular studies have been employed in the diagnosis of TB 
pericarditis. Specifically, nucleic acid amplification (NAA) techniques are now being tested 
to diagnose TB. (10)(10) These techniques amplify genomic deoxyribonucleic acid (DNA) or 
ribosomal ribonucleic acid (RNA) and use the signal to read out gene sequences. However, 
more commonly, the positive microbiology, histology, and polymerase chain reaction (PCR) 
of pericardial fluid are used to define patients with definite TB pericarditis.(9)  
In areas of limited resources, diagnostic procedures and tests are not routinely performed and 
thus there is heavy reliance on indirect ways of determining pericardial TB disease 
status.(11)(12) 
 It is the standard of care to commence anti-tuberculosis treatment before microbiological or 
histology results are available in countries where TB is endemic such as South Africa. (9)(7) A 
number of indirect tests or criteria are used to make a diagnosis of probable TB pericarditis, 
and in the absence of an alternative diagnosis, treatment is commenced. Probable TB 
pericarditis is considered to be the case when there is a pericardial effusion with either proven 
TB in another part of the body (except the heart) with positive microbiology, culture or 
histology results, or a lymphocytic pericardial exudate with elevated adenosine deaminase 





Table1:	  Summarizing	  the	  definition	  of	  definite/proven	  and	  probable/presumed	  TB	  pericarditis*	  
DEFINITE	  DISEASE	   PROBABLE	  DISEASE	  
Isolation	  of	  tubercle	  bacilli	  in	  pericardial	  fluid	  in	  a	  
stained	  smear	  or	  culture.	  
In	  presence	  of	  a	  pericardial	  effusion,	  evidence	  of	  
tuberculosis	  elsewhere	  and/or	  
Histological	  demonstration	  of	  tubercle	  bacilli	  or	  
caseating	  granulomata	  on	  pericardial	  tissue.	  
Lymphocytic	  pericardial	  exudate	  in	  presence	  of	  
elevated	  ADA	  (	  ≥	  40	  IU/l)	  
-­‐	   Presence	  of	  pericardial	  effusion	  an	  appropriate	  
response	  to	  a	  trial	  of	  anti-­‐tuberculosis	  
chemotherapy.	  
*	  Mayosi	  et	  al	  2005(6)	  	  
 
The adverse outcomes of TB pericarditis are well known and they include cardiac tamponade, 
recurrent pericardial effusion, constrictive pericarditis and death. (6,7,13-­‐16).  
The long-term impact of the classification of definite versus probable TB pericarditis on 












2.0 STUDY JUSTIFICATION 
A retrospective study that sought to determine the high long term case fatality rate of patients 
with proven versus non-proven TB meningitis was reported in 2010. It showed 60% mortality 
in proven versus 15% in non-proven cases over 8.71 years. (17)  
A study conducted in India showed that the 18 month mortality in pulmonary TB was 
observed to be highest in patients with smear positive disease (34.7%) and lowest in patients 
in those with smear and culture negative disease (5%). (18) It is not known whether there are 
differences in survival in patients with proven TB pericarditis compared to those with 
probable disease.  
A preliminary analysis to determine this difference was carried out on the 2006 Investigation 
of the Management of Pericarditis in Africa (IMPI) registry. It comprised 111 patients, out of 
which 12 had definite TB pericarditis. This analysis showed that when looking at the short-
term outcomes, there was a trend towards higher mortality in patients with definite versus 
those with probable TB pericarditis. Aspiration of pericardial fluid was only performed in 26 
(14.1%) patients thus limiting the ability to distinguish between definite and probable disease. 
(4)  
It is imperative to repeat this study in a larger population in whom the diagnosis can be 
verified by pericardiocentesis and determine not only the case fatality rate, but also the 
factors that would predict the profile of patients with poor outcomes that would possibly 







3.0 STUDY HYPOTHESIS 
In patients with TB pericarditis, patients with definite disease have worse outcomes than 
those with probable disease despite receiving the same treatment. 
 
4.0 OBJECTIVES 
4.1 Primary Objective 
• To compare overall survival between patients with definite and probable TB 
pericarditis. 
4.2 Secondary Objective 
4.2.1 To identify predictors of mortality in patients with probable and definite disease. 
4.2.2 To determine the incidence rates of recurrent pericardial effusion requiring 
pericardiocentesis, constrictive pericarditis and pericardiectomy in patients with 











5.0 LITERATURE REVIEW 
5.1 Epidemiology 
TB remains a global health issue despite the availability of chemotherapy for more than 60 
years. Before the HIV epidemic, 80% - 85% of reported TB cases were pulmonary in nature 
with the remaining 15% - 20% involving either extrapulmonary sites only or both pulmonary 
and extrapulmonary sites.(19) There have been a rising number of reported extrapulmonary TB 
cases, with as many as 70% being associated with the HIV/AIDS pandemic. (20) 
The rise in the number of extrapulmonary cases has also included an increase in the number 
of TB pericarditis cases. (2)(3) TB is associated with less than 5% of presenting cases of 
pericardial disease in the developed world, but remarkably causes between 50 and 70% of 
disease in the developing world. (3)  (6,9,10).  
Before specific treatment was available, mortality from TB pericarditis was in excess of 80%, 
but with the roll out of anti-tuberculous chemotherapy, mortality declined to less that 10% by 
the 1980’s. (21,22)The advent of HIV-TB co-infection has, however, been associated with an 
increase in not only the incidence of extrapulmonary TB but also a rise in the mortality 
rates.(4) (23) In TB pericarditis, mortality has been shown to range from 17% – 40%, with rates 
being highest in individuals with AIDS.(4,8). 
TB pericarditis continues to receive special attention because it is difficult to diagnose, has 
serious complications, and there exists a paucity of adequate evidence for its management 







5.2 Diagnostic techniques 
Making a definite diagnosis of TB pericarditis requires the identification of M.tuberculosis 
from either pericardial fluid or tissue. In the ideal situation, this would be done prior to 
commencing treatment. In most instances, however, treatment is commenced before culture 
results are available. The clinical decision to do this may be based solely on clinical signs and 
symptoms or indirect laboratory tests, especially in resource poor settings where diagnostic 
facilities may be limited. (9,24) 
Microscopy remains the simplest and most widely used laboratory investigation for detecting 
M.tuberculosis. The fluid aspirate or tissue can be processed using the Ziehl-Neelsen stain in 
search of acid-alcohol fast bacilli (AAFB’s). The sensitivity of these smears ranges from 10% 
- 42%. The process is limited by the need for at least 5 000 bacilli/millilitre to be present for 
AAFB’s to be seen under the microscope. (12) (6).  
 It is good practice to subject samples to both microscopy and culture. Culture remains the 
gold standard for confirming the diagnosis. It has a sensitivity that varies between 50% and 
100%. (12,25). Pericardial tissue samples can also be processed histopathologically. This 
process has a sensitivity of 87% and specificity of 100%. It is less sensitive in patients with 
HIV given the spectrum of changes that may impede the formation of granulomata and 
cavitary disease.(10)  
The severe consequences of a delayed diagnosis have prompted research into techniques with 
improved diagnostic yield. These include nucleic acid analysis by PCR. The sensitivity and 
specificity of pericardial fluid samples subjected to PCR have proved disappointing at 30% 
and 100% respectively.(10) The sensitivity and specificity are better when tissue samples are 




Adenine deaminase (ADA) enzyme assay is an important biomarker than can be used to 
strengthen the diagnosis of TB pericarditis in the absence of a direct method in TB endemic 
areas.(25)  A systematic review evaluating the potential benefits of ADA as an adjunct to 
diagnosis in TB pericarditis showed that when 31 studies were compared, the sensitivity of 
the assay was 88% and its specificity 83%. It had an area under the curve of 0.954 showing a 
great corroboration as a diagnostic tool.(26) This result is further corroborated by the study by 
Reuter et al who found a sensitivity and specificity of 87% and 89% respectively in a TB 
endemic area. (9) These test characteristics justify the use of ADA to strengthen the diagnosis 
in circumstances where bacilli cannot be isolated. 
 
5.3 Complications of TB pericarditis 
Cardiac tamponade: This life-threatening complication arises from the slow or rapid 
compression of the heart by excess amounts of fluid accumulating in the pericardial space. (27) 
As the volume of fluid increases in the pericardial space, the intrapericardial pressure rises. 
When the intrapericardial pressure equals the right atrial and diastolic right ventricular 
pressures, the transmural pressure approaches zero. This severely impedes cardiac inflow and 
may be fatal.  (27)(28)  Symptoms  include shortness of breath, palpitations, cough and chest 
pain with or without weight loss and night sweats. The clinical signs require a high index of 
suspicion and include tachypnea, tachycardia of  ≥ 90 beats per minute, jugular venous 
distention, pulsus paradoxus >10 mmHg, hypotension and attenuated heart sounds. (7,29) (28) 
Treatment of tamponade involves aspirating the pericardial fluid by pericardiocentesis which 




Complications include pneumothorax, hemorrhage, embolism, perforation of the heart 
chambers, and laceration of the great vessels, infection and death. (29) 
When present at diagnosis of TB pericarditis, cardiac tamponade is believed to indicate a late 
presentation and thus advanced disease. This may account for why it is also a predictive 
factor for the subsequent development of constrictive pericarditis.(30,31). The association of 
tamponade with definite and probable TB pericarditis, and thus its role in mortality in the two 
groups is not known. 
Recurrent effusion: In some cases, patients require repeat pericardial aspiration for recurrent 
effusion and tamponade. Effusions that require two or more invasive procedures for drainage 
are called recurrent pericardial effusions.(19). Whilst they may occur in some patients with TB 
pericarditis, they may also signal other underlying disease such as malignancy, uraemia, 
aortic dissection and non-mycobacterial infection. Distinguishing between mycobacterial 
disease and malignancy can be difficult but needs to be ascertained as recurrent effusions in 
both are associated with a poor prognosis, especially when HIV-related (32).   
Constrictive pericarditis: Another important complication of TB pericarditis is constrictive 
pericarditis which generally develops within the first six of months of a patient’s presentation 
with effusive pericarditis.(7,15,22) . It arises from the loss of the normal elasticity, and 
subsequent fibrosis of the pericardial sac. The fibrosis may be partial or global and causes a 
non-pliable pericardial sac. This results in impaired diastolic filling and dissociated 
intracardiac and intrathoracic pressures during respiration.  
The patient may thus present with shortness of breath, palpitations, easy fatiguability, 
abdominal swelling and abdominal pain (from hepatic congestion). On examination there 
may be raised jugular venous pressure, a sinus tachycardia with a low blood pressure and a 




diastole. There may also be pedal oedema and hepatomegaly due to hepatic congestion. If left 
untreated, constriction results in significant morbidity and eventually, mortality. (4).  
Pericardiectomy remains the treatment of choice for patients who develop symptomatic 
constrictive pericarditis. This procedure involves the surgical stripping of the parietal 
pericardium, either partially or completely. It helps to improve the patient’s quality of life and 
is ideally performed in a well-equipped facility in the presence of surgical expertise. The 
procedure is associated with 6 – 12% mortality in the developed world.(33) 
Death: Despite the availability of anti-TB treatment for more than 60 years, TB pericarditis 
still carries an unacceptably high mortality rate.(4)  From the pre-chemotherapy era rates of 
greater than 80%, the number of deaths reduced to less than 10% in the early 1980’s(34), these 
figures have however increased over the past 20 years to between 17% and 40% with the 
advent of the HIV pandemic. (4) Patients receiving appropriate treatment have a variable 
course of recovery widely believed to be related to how early the disease is detected and 
when treatment is commenced. (35) 
 
5.4 Factors associated with mortality in TB pericarditis 
5.4.1 HIV infection 
There have been different studies conducted to ascertain different aspects of the relationship 
between HIV and TB pericarditis. A study by Mayosi et al, showed that clinical 
immunosuppression raised mortality from 17% to 40%. (4) In the study by Hakim et al, it was 
shown that the use of anti-tuberculous therapy with steroids in HIV positive patients resulted 






TB pericarditis can affect an individual at any age. In endemic areas, some series have shown 
that individuals in the third and fourth decades of life are most likely to develop the 
condition. (14) In a study on mortality in patients treated for tuberculous pericarditis, 
increasing age was a predictor of mortality. (4) The underlying reasons for this have not been 
determined. 
 
5.4.4 New York Heart Association Class IV on admission 
Another important feature was the presence of New York Heart Association Class IV 
symptoms at presentation.(31) It would appear that this was related to prolonged pre-treatment 
duration, and would suggest that the longer a patient remains untreated, the less likely they 
are to remain alive despite commencing treatment. These patients tended to suffer poorer 
outcomes as well as longer durations of hospital stay. (35)Atrial fibrillation is self-limiting and 
harmless.(37) 
 
5.4.5 Adjunctive corticosteroids 
The role of corticosteroids in the management of TB pericarditis remains largely unresolved.  
A review of randomized controlled trials on the use of adjunctive steroids in the treatment of 
TB pericarditis showed that steroids could have beneficial effects on morbidity and mortality, 
but that the trials included were too small to be conclusive. They also did not have sufficient 
information regarding the role of adjunctive steroids in HIV- positive and HIV-negative.(15) 
The role of steroids is being re-evaluated in the light of HIV in a large multi-centre 





TB pericarditis is a serious extrapulmonary manifestation of tuberculosis. It is not easy to 
diagnose and it may present with severe complications that include cardiac tamponade, 
recurrent pericardial effusion, constrictive pericarditis and death. Factors which include age, 
HIV co-infection and cardiac tamponade at admission are known to influence outcome in 
patients admitted with the condition. Patients with proven meningeal and pulmonary TB 
appear to have worse outcomes than those with presumed disease. It is not known whether 

















6.1 Study design 
The study was a combined retrospective and prospective cohort study in which registry and 
file based data on all patients who had pericardiocentesis for pericardial effusion from 
January 2006 to December 2010 were examined. 
6.2 Population and Sampling 
The study was conducted at the Groote Schuur Hospital (GSH), Cape Town, Western Cape 
Province of South Africa. Patients who underwent pericardiocentesis for suspected TB 
pericarditis and were started on anti-TB treatment were enrolled. This included patients 
enrolled onto the IMPI Africa Pericarditis registry with suspected TB pericarditis. 
Patients were enrolled consecutively and followed up. These patients had to be within the 
first seven days of commencing anti-tuberculous therapy, and were recruited into one of two 
categories – those fitting the criteria for being definite TB pericarditis and those falling into 
the probable TB pericarditis group. 
Suspected TB pericarditis is defined as a patient presenting to the hospital with a clinical 
syndrome of pericardial disease which is suspected to be caused by TB on the basis of 
clinical and/or laboratory findings leading to the commencement of anti-TB treatment as per 
national protocol.(9) (38) 
Definite and probable TB pericarditis have been defined under the introduction section of this 







6.3 Data Collection 
Information regarding patient demographics, clinical characteristics, laboratory results and 
treatments instituted was collected from in-patient hospital folders using a standardised data 
extraction form (appendix B). Where available, patient outcomes were also recorded from 
folders. 
Where there was no outcome noted, patient files from referring clinics were traced, eKapa 
and Clinicom databases searched, and also efforts made to obtain death certificates from the 
Department of Home Affairs. The date of censure of follow-up was 1 January 2012. 
6.4 Identification of participants 
Enrolment was based on a follow-up of all patients who underwent pericardiocentesis during 
the study period at the GSH. Further, lists of all processed pericardial fluid specimens were 
obtained from the microbiology laboratory to ensure that no patients were missed, in addition 
to the records obtained from the catheterization laboratory. The aim was to enrol all the 
patients who underwent pericardiocentesis and were seen at the GSH between January 2006 










6.5  INCLUSION AND EXCLUSION CRITERIA 
6.5.1 Inclusion criteria.   
• Pericardial effusion confirmed on echocardiography. 
• Pericardiocentesis and/or pericardial biopsy performed, and 
• Within 1 week of starting anti-TB treatment. 
 
6.5.2 Exclusion criteria 
• Pericardial disease from other causes, e.g., malignancy, penetrating chest trauma in 
the preceding 12 months or uremia at initial assessment. 
 
6.6 Sample Size Calculation. 
Sample size was not calculated as the study sought to assess the outcomes of all the patients 
who underwent pericardiocentesis and were commenced on anti-TB treatment between 1st of 









6.7 Definitions of variables and outcomes 
The main variables used included: 
• Cardiac tamponade on admission as determined by the presence of  a  pulsus 
paradoxus  >10 mmHg , tachycardia >90 bpm, raised jugular venous pressure >5 cm 
and an echocardiographically confirmed pericardial effusion with at least one of the 
following : i) swinging heart,  ii) diastolic collapse of right ventricle, left atrium 
and/or left ventricle, iii) failure of inferior vena cava to collapse on inspiration and/ or 
iv) tricuspid flow increases and mitral flow decreases during inspiration (reverse in 
expiration).  
• Pericardial fluid microscopy for acid-alcohol fast bacilli (AAFB) and culture for M. 
tuberculosis  
• Pericardial histology to identify caseating granulomata and AAFB. 
• Microscopy, culture or biopsy findings of TB from another part of the body. 
•  HIV serology test 
• Atrial fibrillation on admission prior to pericardiocentesis as documented  in the 
clinical record 
• Diagnosis of constrictive pericarditis, the need for repeat pericardiocentesis or the 
need for pericardiectomy based on the diagnosis of the attending physician and 
documented in the clinical record. 






6.8 Field Management 
The study was at GSH and information was obtained from the records department and 
cardiology and microbiology. Where records were incomplete, an attempt was made to trace 
files from the referring clinics and use the eKapa and Clinicom databases. We also made use 
of the Department of Home Affairs death records database. 
6.9 Quality Control 
6.9.1 Improvement of Validity 
Where information was missing, referring clinics were contacted and an attempt made to 
verify information. Where information was completely unavailable, no assumptions were 
made. 
6.9.2 Improvement of Reliability 
Reliability was ensured by the use of a standardised data extraction tool, and the use of 
multiple sources of information for each patient.  
6.9.3 Pilot Study 









7.0 DATA MANAGEMENT AND STATISTICAL ANALYSIS PLAN 
The data was analysed using STATA version 11.1. Associations were explored using 
bivariate and multivariate associations prior to any further analysis. Data were expressed as 
median and interquartile ranges for continuous variables and counts with percentages for 
categorical variables. Comparisons between patient groups (definite TB pericarditis, probable 
TB pericarditis with TB in another part of the body (TB elsewhere) and probable TB 
pericarditis with no TB elsewhere) were performed using chi-squared or Fisher’s exact tests 
based on the numbers of patients in each group.  
7.1 Kaplan Meier survival curves were constructed to compare survival rates between 
patients with definite TB pericarditis, probable TB pericarditis with TB elsewhere and 
probable TB pericarditis with no TB elsewhere. 
7.2   Cox proportional hazards regression was performed to identify the factors associated 
with mortality in patients with definite and probable disease. 
7.3 Incidence rates were calculated using standardized morbidity ratios. This was based on 
the number of new cases of complications during a given time. The complications for 
which incidence were calculated were the incidence of recurrent pericardial effusion, 
constrictive pericarditis and pericardiectomy. 
8.0 STUDY LIMITATIONS 
This research was based on a folder review, and collected registry data, and thus the validity 
of the findings depended on the quality of the data collected by clinicians who did not have a 
standard way of recording or collecting the information required.  
Not all patients provided national identity numbers or correct contact information on 




could they be traced via the Home Affairs Death records registry. Foreign patients could not 
be traced via the Home Affairs death records limiting that as a tracing route.  
9.0 ETHICS AND COMMUNICATIONS 
All data were initially collected with patient identifiers for the sake of correct follow-up, 
however, confidentiality was maintained during the process of data collection. As this is a 
folder based review, written consent was not obtained from all the patients. After data 
collection, the patients were de-identified to ensure their confidentiality. 
9.1 Potential Harms 
There was no potential harm as a result of this folder review. 
9.2 Potential Benefits 
     The results of this study will be used to inform the management of TB pericarditis and 
further research in the field. The results will be an important source of information on the risk 
stratification of patients diagnosed as either definite or probable TB pericarditis. 
9.2 Results and Communications 
The findings will be presented at local, national and international conferences. The main 
findings will be published, and efforts will be made to ensure that the findings influence 
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The main objective of this literature review is to summarize what is known about the 
determinants of survival in patients diagnosed with TB pericarditis with emphasis on definite 
and probable disease. 
Studies describing the epidemiology and outcomes of this condition and highlighting the 
complications will be included. Finally, there will be a summary of the gaps in the 
information available regarding survival in TB pericarditis. 
 
1.2 Search strategy 
Studies on TB pericarditis were found by searching PubMed, CINAHL Plus with full text, 
Google Scholar and the Cochrane Library. Studies with relevant key terms in their titles were 
identified, abstracts read and then the full text article. They included any published study with 
information on mortality or survival outcomes. Additional studies were identified from 
reference lists of original articles, reviews and treatment guidelines. Both qualitative and 
quantitative studies were included if they were in alignment with the objectives of the 
literature review. 
From PubMed, 76 hits were retrieved, The Cochrane library had one review article and 10 
listed trials, and 7600 hits were found on Google Scholar. Starting from the Cochrane Library 
and then PubMed databases, studies with relevant key terms were identified. Additional 
articles were then retrieved from Google Scholar via reference lists of original articles, 
reviews and treatment guidelines. Articles were restricted to those written in or available as 




            
Search terms included “mortality in tuberculous pericarditis”, “TB pericarditis/mortality”, 
"constrictive pericarditis”, “pericardial effusion”, “pericarditis tuberculous/complications”, 
“survival in tuberculous pericarditis,” ”proven versus probable disease tuberculosis,” 
“definite tuberculous pericarditis,” "probable tuberculous pericarditis” 
 
 1.3 Relevance of included studies. 
This literature review is based on studies conducted in both the developing and developed 
world. It includes systematic reviews, randomized controlled trials, cohort studies, case-
control studies and conference abstracts and text book material.  Where relevant, studies 
conducted prior to the adoption of specific anti-TB chemotherapy are included. 
 
Studies were selected to include those that described survival outcomes, predictors of 
mortality, disease progression, predictors of complications, comparison with other 
extrapulmonary TB outcomes, and also for relevant descriptions before and after the onset of 
the human immunodeficiency virus (HIV) pandemic. 
 
Selected articles were thus from peer-reviewed journals, clear in their sampling techniques 
and had a clear study hypotheses related to the topic at hand. 
Whilst case reports provide extensive descriptions on the recruited patients, they were 
excluded from this literature review due to the difficulty that arises from attempting to make 







2.0 LITERATURE REVIEW ON FACTORS INFLUENCING SURVIVAL IN 
TUBERCULOUS PERICARDITIS 
 
2.1 Disease epidemiology and description. 
Few, if any, infectious diseases have caused as much morbidity and mortality in the world as 
has TB. In 2010, there were approximately 8.5 to 9.2 million cases of TB, and between 1.2 
and 1.5 million deaths worldwide - 59% of these cases occurred in South East Asia and 26% 
in Africa.(1) 
 
The burden of TB which is primarily pulmonary in nature may also manifest with 
extrapulmonary disease including TB pericarditis. This is particularly important with the 
advent of the HIV/AIDS pandemic which is recognized as the most common risk factor 
associated with the development of extrapulmonary TB. (2) 
TB accounts for 4% of the cases of pericardial disease in the developed world, but 
remarkably causes between 70% - 90% of the new cases in the developing world. (3-­‐5) 
Prior to the adoption of the current isoniazid and rifampicin-based drug regimes, TB 
pericarditis caused mortality in nearly all affected cases. The roll-out of treatment during the 
last century saw this figure decrease to approximately 10%. The advent of HIV-TB co-
infection has resulted in a change in the epidemiology of TB pericarditis with recent studies 
showing up to 40% mortality at 6 months despite starting adequate treatment. (6)(7)(8). 
 
TB pericarditis generally develops from the spread of M.tuberculosis bacilli from the 
mediastinal, peritracheal or peribronchial lymph nodes to the heart. Occasionally 




It is postulated that there are four pathophysiological stages of the disease: (1) a dry stage 
which is characterized by a fibrinous exudate, a high concentration of mycobacterial bacilli 
and early scattered granuloma formation. This stage is caused by a tuberculoprotein 
hypersensitivity reaction; (2) an effusive stage that is associated with a serosanguineous 
lymphocytic effusion; (3) an absorptive phase that is characterized by a granulomatous 
inflammation and caseous necrosis; and (4) the constrictive phase which results from the 
fibrosis of both the visceral and parietal pericardium. This encases the heart and may become 
calcified, thus compromising the normal function of the heart and resulting in constrictive 
pericarditis. (9) 
Symptoms of TB pericarditis are generally vague and non-specific. They arise from immune 
responses that are triggered by bacterial proteins as the bacilli penetrate the pericardium. 
Symptoms may include fever, night sweats, and malaise and weight loss. As the disease 
progresses, there is worsening shortness of breath, cough, palpitations and chest pain.(10) (9) 
 
 This literature review focuses mainly on the effusive presentation of the disease. 
 
2.2 Factors associated with death 
The description of a high mortality in patients treated for TB pericarditis has prompted this 
study of risk factors of poor outcome in TB pericarditis (4) . Several factors are explored 
including certainty of diagnosis, HIV - TB coinfection, presence of cardiac tamponade, 
cardiovascular functional status, the presence of atrial fibrillation, age and gender. 
2.2.1 Definite versus probable disease 
An important aspect of pericardial disease caused by TB that has not received much attention 
is that of the influence of a definite or probable diagnosis on the survival of a patient 




A definitive diagnosis is centered on the isolation of the M.tuberculosis in pericardial fluid or 
a pericardial tissue specimen.(11) This sample is obtained either by pericardiocentesis and/or 
open drainage with pericardial biopsy. Pericardiocentesis is an invasive and potentially fatal 
procedure that is ideally performed under echocardiographic or fluoroscopic guidance. It is 
associated with complications such as myocardial perforation, air embolism, arrhythmias and 
pneumothorax.(11)  
Depending on the laboratory methods used to process the specimen, the diagnostic yields 
range from 30% to 76%. (12) Aspirated fluid needs to be apportioned for various tests 
including microscopy, culture, biochemical analysis, cytology and PCR. It has been 
suggested that extrapulmonary samples of TB infection are frequently paucibacillary. 
Furthermore, they may contain inhibitors that undermine the sensitivity of nucleic acid 
amplification-based techniques.(13,14). Pericardial tissue can also be tested for granuloma 
histologically, but even this is associated with a low yields, especially in HIV positive 
patients.(15) . 
The simplest test remains microscopy which needs a bacillary density > 5,000 
bacilli/millilitre to yield a positive result. The procedure is user dependent and thus subject to 
human error including cross-contamination. It also cannot distinguish between 
M.tuberculosis and non-tubercular mycobacteria. (10) 
The gold standard for detecting TB remains culture.(16) According to Reuter et al, culture 
specimens which tend to have a sensitivity ranging from 74-95% in cavitary pulmonary 
disease, decline to a sensitivity of between 25% and 30% in extrapulmonary disease.(14) In 
pericardiocentesis, the diagnostic range fluctuates between 30% and 76%. This means that a 





In an endemic area where pericardiocentesis cannot easily be performed, a clinical diagnosis 
of TB pericarditis can be made on the basis of a prediction model that includes the following 
features: weight loss, night sweats, fever >38◦ C, serum globulin >40g/l and a leukocyte count 
<10  cells/liter in the presence of an echocardiographically confirmed pericardial effusion. 
The diagnostic index allocates 1 point each to weight loss >10 kg and night sweats, 2 points 
to fever, and 3 points each to a raised serum globulin and a normal leukocyte count. A score 
of 6 or more is associated with 86% sensitivity and a 76% specificity to diagnose TB 
pericarditis. This prediction model, also called the Tygerberg score, is invaluable where 
facilities for safe pericardiocentesis are absent, or where the procedure is not indicated, and 
treatment needs to be started empirically. (14) 
The Tygerberg score is summarized as follows: 
Table B.1: Showing Tygerberg index 
Clinical	  Variable	  on	  
Admission	  
Point(s)	   Score	  Weight	  
Weight	  loss	  >10kg	   1	   0.13	  
Fever	  >38◦	  C	   2	   0.17	  
Night	  sweats	   1	   0.09	  
Serum	  globulin	  >40	  g/l	   3	   0.33	  
Blood	  leukocyte	  
count<10x109	  	  
3	   0.28	  
 
Because the clinical features of TB pericarditis are not specific, attempts need to be made to 
improve confidence in the diagnosis in the absence of mycobacterial isolation. In 
circumstances where clinical suspicion of TB is high but fluid aspirate does not isolate any 




 One of the most important indirect methods available is the use of adenosine deaminase 
(ADA) levels in pericardial fluid. A level in excess of 40 IU/L is a useful indicator of TB 
infection in the presence of clinical features. ADA has a sensitivity of 87% and a specificity 
of 89% for diagnosing TB pericarditis.(17)  Other factors like gamma interferon (IFN-γ) levels 
of ≥200pg/L can also be used. 
This means that while a diagnosis of definite disease depends on the isolation of 
mycobacteria from pericardial aspirate or tissue, a probable diagnosis will be presumed based 
on the isolation of mycobacteria elsewhere in a patient with otherwise unexplained 
pericarditis; and/or a lymphocytic pericardial exudate with high ADA or IFN-γ levels; and/or 
an appropriate response after a trial of therapy. (18) 
 
 
 Table B.2: Showing definite and probable definitions* 
DEFINITE	  DISEASE	   PROBABLE	  DISEASE	  
Isolation	  of	  tubercle	  bacilli	  in	  pericardial	  fluid	  
by	  microscopy,	  culture	  and	  PCR.	  
In	  presence	  of	  a	  pericardial	  effusion,	  proof	  of	  
tuberculosis	  elsewhere	  and/or	  
Histological	  isolation	  of	  tubercle	  bacilli	  in	  
pericardial	  tissue.	  
Elevated	  ADA	  ≥	  40	  IU/l	  and/or	  predominant	  
lymphocytic	  cells	  in	  aspirated	  pericardial	  
fluid	  and/or	  
-­‐	   Presence	  of	  pericardial	  effusion,	  clinical	  
features	  and/or	  an	  appropriate	  response	  to	  
a	  trial	  of	  anti-­‐tuberculosis	  chemotherapy.	  






Studies comparing definite and probable disease outcomes:  
A study that compared survival outcomes in patients with definite and probable disease was 
conducted prior to the availability of isoniazid and rifampicin-based treatment regimens. 
Based on culture results for tubercle bacilli isolation, it showed a higher mortality in patients 
with proven versus non proven TB pericarditis, (83% versus 6% respectively). The 
investigators concluded that in cases where bacilli were easily detectable from pericardial 
fluid, prognosis was grave.(19) 
A study by Colebunders et al, showed that patients who had negative smears but positive 
culture results had minimal disease with low bacillary counts. Mortality was also lower in 
this group of patients. The investigators thus inferred that infectivity and mortality in smear 
negative disease is lower, and consequently, less intense chemotherapy is needed to treat the 
condition. (20) This finding was supported by a trial in Indian patients which showed that 
mortality at 18 months was highest in those with positive smears (34.7%) and lowest in those 
who were both smear and culture negative (5%). (21) 
Additionally, a retrospective study on mortality in patients treated for meningeal TB showed 
that there was a higher long term mortality in patients with proven meningeal tuberculosis as 
compared to those with non-proven disease (78% and 38% respectively).  (22) This study 
followed up patients for a maximum of 8.71 years and the findings raised the question that 
perhaps management strategies for patients with proven disease may require revision. There 
have been no studies of a similar nature to compare survival outcomes in patients with proven 
and presumed TB pericarditis. 
The outcomes noted in the pulmonary TB and meningeal TB patients did not establish 
whether the bacillary densities in patients with proven versus presumed disease were 
different. The studies did however raise questions about the adequacy of patient monitoring, 




possibility of these findings being possible across all forms of TB, including TB pericarditis. 
(23) 
 
2.3.2 HIV-TB co-infection 
In developing countries where TB is endemic, it is the sentinel disease for HIV infection.(24)  
Patients with both TB and HIV disease have been shown to present with fewer detectable 
AAFB's in their sputum and less frequent pulmonary cavitary lesions than HIV negative 
patients of similar demographics. HIV is also associated with more frequent extrapulmonary 
disease. (25) 
 
A study by Reuter et al, showed that the stage of immunodeficiency, the risk of disseminated 
TB and other serious opportunistic infections and ultimately death, all correlated with 
absolute CD4+ lymphocyte cell counts. Outcomes were evidently better in patients with 
counts >200 cells/µl. Only 25% of these cases appeared to have proven TB elsewhere in the 
body.(26).  This meant that in the majority of patients, disease only involved the pericardium. 
This study was important because it was conducted in HIV positive patients that had no 
access to anti-retroviral treatment and so it helped to shed light on the clinical evolution of 
TB pericarditis in different stages of HIV disease.(27) An earlier study by the same authors 
also showed that a history of previous TB occurred less frequently in HIV positive patients 
and did not seem to influence the development of constrictive pericarditis or even predict 
mortality. (11)   
 
An observational study that described mortality in patients treated for TB pericarditis in Sub-
Saharan Africa showed that the mortality in patients with AIDS was 40% at 6 months, and 




pericardiocentesis was only performed in 14.1% of the participants and a definite diagnosis 
established in 7.3%. The independent predictors of mortality in this study were increasing 
age, AIDS, pulmonary TB, proven non-TB pericarditis and use of anti-retroviral drugs.  They 
also showed a decrease in mortality amongst those who underwent pericardiocentesis.(8)  
 
2.3.3 Age and gender 
TB pericarditis can affect an individual at any age. In endemic areas, various studies have 
shown the second, third and fourth decades of life to be the most likely to develop the 
condition.(18,28) In a study on mortality in patients treated for TB pericarditis, increasing age 
was a predictor of mortality.(4)  Increasing age has also been shown to be a predictor of higher 
morbidity and mortality after pericardiectomy, thus increasing the overall mortality from TB 
pericarditis.(29) 
 
Various studies have shown that the proportion of males to females affected by TB 
pericarditis differs from region to region. Proportions range from a male: female ratio of 
2.7:1, 1:1 and 1:3. (30). Local studies have also shown contrasting results on mortality when 
compared by gender. One study showed that poor black women were more likely to present 
with, and die from TB pericarditis, than men of the same racial and economic background.(14)  
Whilst another study showed that mortality was higher in men than in women when 
controlling for age. (4) These results point to the importance of following up all patients 








2.3.4 Adjunctive corticosteroids 
A systematic review on the role of steroids in addition to anti-TB drugs in the treatment of 
TB pericarditis showed that the role of steroids remains largely unproven. (31) The studies 
included in the review showed a reduced case-fatality rate and a favourable clinical outcome 
at 18-24 months of follow-up. The authors concluded that the findings were statistically 
inconclusive because of the low number of patients included in the review.(31) 
There have been trials conducted in an attempt to investigate this role both prior to the HIV 
pandemic and after its onset. 
Prior to the HIV pandemic, adjunctive corticosteroids showed favourable outcomes when 
received in combination with the recommended TB chemotherapy. Strang et al., showed that 
long term survival was better in those who had received steroids than in those who had not 
(94% and 85% respectively). The steroid-receiving arm of the trial also had fewer cases that 
required pericardiectomy as opposed to the placebo arm (21% and 30% respectively), thereby 
reducing overall morbidity as well. Long term mortality was however not affected in these 
patients. (6,32,33)   
With the onset of the HIV pandemic, a double blinded randomized trial in HIV positive 
patients with TB pericarditis was conducted to evaluate the role of steroids in addition to TB 
treatment. In this trial, Hakim et al showed that mortality was significantly lower in the 
steroid arm of the trial. This reduction was accompanied by lower morbidity levels in the 
same study arm. The recommendation of the investigators was for the inclusion of steroids to 
TB pericarditis treatment regimens. (7)The gains of the study are yet to be confirmed in a 







2.3.5 New York Heart Association functional class and atrial fibrillation at presentation 
A study on the predictors of constrictive pericarditis showed that patients who presented in 
New York Heart Association stage IV with features of right-sided heart failure including 
paedal edema, ascites and hepatic congestion, were more likely to progress to a constrictive 
stage and more at risk to die from TB pericarditis. (34) This is thought to be because the 
patients may already be in an effusive constrictive stage of the disease as opposed to a purely 
effusive stage. On pericardiocentesis, the symptoms would initially be relieved; however, 
irreversible changes would have already been set in motion. There is presently no known 
medical treatment for this stage of the disease.  
 
Atrial fibrillation is common in patients with TB pericarditis. A prospective trial investigating 
its prevalence and natural history in patients with TB pericarditis was recently conducted. It 
showed that fibrillation was present in 25% of those enrolled and by the end of the follow-up 
period there was no significant association between atrial fibrillation and mortality. The 
investigators concluded that the atrial fibrillation in these patients was secondary to 
inflammatory processes caused by the underlying disease and as such, treatment of the 
disease resolved its presence.(35) 
These findings are in contrast to previous studies conducted in the Transkei by Strang et al in 
which atrial fibrillation was shown to be present in less than 3% of the studied population. (6).   
 
2.3 Complications of TB pericarditis that may be associated with outcome. 
2.3.1 Cardiac tamponade 
Cardiac tamponade is an early complication of TB pericarditis. It is a life-threatening 
condition that arises from the compression of the heart by excess amounts of fluid 




becomes elevated throughout the cardiac cycle, and diastolic filling is therefore 
compromised. 
The clinical signs include tachycardia of ≥ 90 beats per minute, pulsus paradoxus of ≥ 10 
mmHg, hypotension and attenuated heart sounds. (10) 
 Cardiac tamponade may be the presenting feature of TB pericarditis.(37). In different studies, 
it has been shown to be present at admission in 60% - 90% of patients at admission. (36)  (37)In 
a series by Suwan et al., tamponade on admission was a predictive factor for the subsequent 
development of constrictive pericarditis.(34,38)  This was not confirmed in a study by Hakim et 
al who showed that tamponade does not always predict progression to constriction as the 
majority of  the patients enrolled in their study  presented with tamponade, but none went on 
to develop constriction.(39) Neither study investigated an association between tamponade and 
mortality. 
2.3.2 Recurrent pericardial effusion 
In a proportion of TB pericarditis patients, recurrent pericardial effusions occur. These are 
defined as effusions that require two or more invasive procedures for drainage.(40). Whilst 
they may occur in some patients with TB pericarditis, they may also signal other underlying 
disease such as malignancy, uraemia, aortic dissection and non-mycobacterial infection. 
Distinguishing between mycobacterial disease and malignancy can be difficult but needs to 
be ascertained as recurrent effusions in both are associated with a poor prognosis, especially 
when HIV-associated (41).   
 
2.3.3 Constrictive pericarditis 
One of the most important complications of TB pericarditis is constrictive pericarditis. This 
condition is characterized by the inflammation, thickening and eventual fibrosis of the 




results in the limitation of diastolic ventricular filling. As the scar shrinks, further 
compression of the heart occurs especially around the right side of the heart and around the 
great veins.  The resulting signs and symptoms produced are due to systemic venous 
congestion. (5) 
In developing countries with a high prevalence of TB, constrictive pericarditis is considered 
to be of tuberculous etiology until proven otherwise. (42) (6,8)  Early studies suggested that the 
early institution of medical therapy was associated with lower constriction and death rates, (43) 
but it is now shown that between 4% and 50% of cases go on to die from constriction related 
complications, making constriction worth preventing regardless of etiology. (44) 
Unfortunately, pericardial constriction may be the first presentation of TB pericarditis with 
no apparent symptoms to suggest a previous effusive stage. (45). 
 
Pericardiectomy remains the treatment of choice for patients who develop symptomatic 
constrictive pericarditis. This procedure involves the surgical stripping of the parietal 
pericardium. The stripping may be partial or complete. It helps to improve the patient’s 
quality of life but needs to be performed in a well-equipped facility under surgical expertise. 
It is associated with 6 – 12% mortality in the developed world.(42) Pericardiectomy is also 
important for the high morbidity it is associated with. According to a nation-wide American 




The literature has shown that TB pericarditis is a serious and potentially fatal extrapulmonary 
manifestation of tuberculosis. The condition is not easy to diagnose and it may present with 




pericardial effusions and death. Several factors including age, gender, HIV co-infection, 
cardiac tamponade at admission and adjunctive steroid use are known to influence the 
outcomes in patients admitted with the condition.  
There is also evidence that culture positive or proven pulmonary and meningeal TB may be 
associated with a worse outcome than culture negative or presumed disease. To the best of 
my knowledge, no information exists regarding the relationship between proven and 
presumed status of diagnosis and outcome in TB pericarditis. 
I have embarked on a prospective observational study in the IMPI registry to test whether 
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Background: There is evidence that proven pulmonary and meningeal cases of tuberculosis 
(TB) are associated with a worse outcome than presumed cases. 
 Aim: To determine if survival is comparable for definite versus probable TB pericarditis 
among patients treated for TB pericarditis at the Groote Schuur Hospital (GSH). 
Methods:  A retrospective cohort study was conducted on newly diagnosed TB pericarditis 
cases referred to the GSH for pericardiocentesis from January 2006 to December 2010. Based 
on a folder review, baseline characteristics and laboratory findings were collected, and 
patients assigned as definite or probable TB pericarditis. A definite diagnosis was one in 
which pericardial fluid or tissue tested positive for TB, whilst a probable diagnosis was based 
on negative microbiological findings in the presence of clinical and indirect laboratory 
findings. The probable group was further divided into those with proven TB in another part of 
the body (except the heart) and those with probable TB.  
Results: 192 patients that had a pericardiocentesis for suspected TB pericarditis were 
followed up for a median of 52.9 weeks (15.14 - 90.6). 93 (48.4%) of the patients had definite 
disease, 20 (10.4%) had probable disease with TB elsewhere and 79 (41.1%) had probable 
disease with no TB elsewhere; mortality was 19 (20.4%), 4 (20%) and 13 (16.5%), 
respectively over the follow-up period (p = 0.799).  The predictors of mortality were low 
diastolic blood pressure, presence of cardiac tamponade and older age. The overall incidence 
rate of recurrent pericardial effusion was 47.1 cases per 1000 person-years; of constrictive 
pericarditis was 132.2 cases per 1000 person-years and of pericardiectomy was 34.4 cases per 




Conclusions: The survival and outcome of definite and probable TB pericarditis are the 
same. With attention to clinical parameters on admission, it is possible to determine which 
patients need more clinical care. 





















More than 100 years after the identification of Mycobacterium tuberculosis (M. tuberculosis) 
by Robert Koch, TB remains a global health problem, disproportionately affecting the 
developing world.  TB pericarditis is an important extrapulmonary manifestation of TB that is 
associated with a significant level of morbidity and mortality. (1,2).  
We aimed to determine if patients with definite TB pericarditis suffered worse outcomes than 
those with probable disease despite receiving the same treatment. 
Methods 
The study was a retrospective cohort study in which files of all patients who underwent 
pericardial aspiration for suspected TB were reviewed. It was conducted at the GSH, Western 
Cape, South Africa. Folders were selected for review if aspiration occurred between January 
1 2006 and December 31 2010.  Inclusion into the study was based on the patient being 
within their first week of TB treatment and having had a pericardiocentesis and/or pericardial 
biopsy performed in the presence of a confirmed effusion for suspected TB pericarditis. They 
were excluded if they had pericardial disease from any other cause such as malignancy or 
uremia, or were within one year of having experienced penetrating chest trauma.  
Baseline characteristics of the patients and any subsequent procedures such as 
pericardiectomy were collected from folders. Patients were classified as definite TB 
pericarditis, probable TB pericarditis with proven TB elsewhere in the body or probable TB 
with no proven TB elsewhere in the body, depending on laboratory results. Definite TB 
pericarditis is characterised by isolation of tubercle bacilli from pericardial fluid or tissue by 
microscopy, culture or polymerase chain reaction (PCR). Probable TB pericarditis is based on 




adenosine deaminase (ADA) ≥40 IU/L and/or a predominantly raised lymphocyte count in 
the pericardial fluid, and/or an appropriate response to TB chemotherapy. (3) 
All patients were managed at primary care facilities from where they received TB treatment 
as per national guidelines (4). They were also commenced on anti-retroviral therapy (ART) at 
the discretion of their primary care physicians. They were referred back to the GSH in the 
event that they developed symptomatic constriction or needed pericardiectomy. Details on 
patient mortality or subsequent outcome were collected from patient folders, the Clinicom 
electronic database, patient tracing and the Home Affairs death records. All patients without 
any outcome despite attempts at tracing were excluded from the analysis. All patients were 
censored for follow-up on 1 January 2012. 
Retrieved patient data was recorded on a standardized form. All data was analysed using 
STATA 11.1. Associations of variables were made with chi-square tests and Fishers exact 
measurements where appropriate to compare characteristics between the three groups of 
patients. For the survival analysis, Kaplan-Meier curves were used and Cox proportional 
hazards regression used to determine predictors of mortality in the study population. 
Incidence rates were calculated as the number of new cases of complications during a period 
of time divided by the person-time at risk. The research was approved under the Human and 










During the study period, a total of 349 patients were identified to have undergone 
pericardiocentesis. Of this total 157 (45%) were excluded due to incomplete data baseline or 
outcome data. In the remaining 192 patients (55%), 93 (26.6%) were classified as definite TB 
pericarditis, 20 (5.7%) as probable TB with proven TB elsewhere in the body (except the 
heart) and 79 (22.6%) as probable TB pericarditis with no TB elsewhere.  
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† included missing folders, patients that could not be traced due to insufficient follow-up information. 14 
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Duration* (days), median (IQR) 
Pulse (bpm), median (IQR) 
 
 
 Systolic BP, median (IQR) 
 Diastolic BP, median (IQR) 
 Pulse pressure, median (IQR) 
 Mean arterial pressure, median 
(IQR) 
 
 §Atrial Fibrillation, (n=124) (%) 
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 Globulin (gm/l), median (IQR) 
 
**Tested for HIV (n=181) 
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History of previous TB, n (%) 
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*Duration of symptoms before admission 
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§Only 124 out of 192  patients had a record of AF, of whom,  27 patients with definite TB pericarditis had presence / absence of AF 
recorded, 20 of those with probable disease and TB elsewhere  and  X  only 77 patients with probable TB with no TB elsewhere had a record 
of presence/absence of  AF 
 
** Only a 181 out of 192 patients were tested for HIV.(88 with definite TB had a record of  an HIV test, 20 patients with probable and TB 
elsewhere and  73 with probable and no TB elsewhere had a record of an HIV test) 
 
¶only 184 out of the 192 patients had a record of presence or absence of tamponade, out of which, 87 patients with definite TB had a record 
of presence or absence of tamponade; 20 of those with probable TB with TB elsewhere had a record of presence or absence of tamponade 
and only 77 of the 79 patients admitted with probable disease and no TB elsewhere had a record of absence or presence of tamponade. 
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(Table 1) summarises the baseline characteristics of the study participants. A total of 192 
patients were enrolled and then followed up for a median of 52.9 weeks (15.14 - 90.6). Of 
these, 93 (48.4%) were classified as having definite disease, 20 (10.4%) as having probable 
disease with TB proven elsewhere in the body and 79 (41.1%) as probable disease with no 
TB elsewhere in the body.         
There was a difference in age distribution between the three groups with the median age in 
those with definite disease higher than the median age in the other two groups. The median 
age in those with definite disease was 34 years (30 - 45); 30 years (24.5 – 37) in those with 
probable disease with TB elsewhere and 30 years (26 – 41) in those with only probable 
disease; (p = 0.020).  
There was no difference in the proportion of males and females enrolled when all three 
groups were compared. With males comprising 57 (61.3%) of those with definite disease, 10 
(50%) of those with probable disease and TB elsewhere and 40 (50.6%) of those with 
probable disease only; (p = 0.322).	  
Based on clinical features, there was no difference in the duration of symptoms before 
admission between the three groups. The median duration of symptoms was 28 days (14 - 31) 
in the definite group, 24 days (14 - 38.5) in the probable with TB elsewhere group and 23 
days (14 – 42) in the patients with probable but no proven TB elsewhere group; (p = 0.692).  
When compared by blood pressure (BP) and pulse rates, there was no difference between the 
definite, probable with TB elsewhere and probable disease only groups. The median systolic 
pressure was 108 mmHg (97 -114) in the definite group; 100.5 mmHg (99 - 108) in the 
probable with TB elsewhere group and 105 mmHg (96 – 117) in those with probable but no 
TB elsewhere; (p = 0.823). Furthermore, the median diastolic pressure was 70 mmHg (64 – 




proven TB elsewhere and 70 mmHg (60 – 80) in those with probable disease but no TB 
elsewhere; (p = 0.670). The median pulse in all three groups was similar (p = 0.180). Those 
with definite disease had a median pulse of 114 bpm (101 – 126), those with probable disease 
and TB elsewhere 120 bpm (99 – 120) and in those with probable disease but no TB 
elsewhere 110 bpm (96 – 122). Additionally, the pulse pressure and mean arterial pressure 
were similar in the three groups; (p = 0.586 and p = 0.657, respectively). 
Median ADA levels were lower in the patients with probable disease with no TB elsewhere 
55 IU/l (30 – 81.9) than in those with probable disease but proven TB elsewhere, 75.3 IU/l 
(42.4 – 121) and those with definite disease, 73 IU/l (52.7 - 99); (p = 0.025). The latter two 
groups had similar ADA levels. The median globulin levels were highest in patients with 
definite disease, 54.5 gm/l (47.6 – 63), followed by those with probable disease with no TB 
elsewhere, 48 gm/l (43 – 55)  and those with probable TB with TB elsewhere, 46.5 g/l (44 – 
58); (p = 0.008). 
The median duration of follow-up in all three groups was similar, (p = 0.561). Patients with 
definite disease had a median follow up of 52 weeks (21 – 102.6), those with evidence of TB 
elsewhere, 60 weeks (18.5 – 77.3) and those with probable disease but no TB elsewhere, 55 



















Fig (2) presents the Kaplan-Meier survival curves of patients with definite disease, with 
probable disease with proven TB elsewhere and those with probable disease with no TB 
proven elsewhere.  
Based on the analysis, the three groups do not differ in terms of survival; (Log rank: chi-







Using Cox regression analysis, we investigated the influence of selected demographic 
characteristics, clinical features and laboratory findings on mortality. The factors associated 
with mortality in the enrolled patients were examined using both a univariate and multivariate 
analysis. A step-wise model building was performed and the variables selected for regression 
analysis in the model were based on statistical significance. 
A multivariate model was fitted based on step-wise model building.  

















	   	   	   	   	   	   UNIVARIATE	  ANALYSIS	   	   	   	   	   	   MULTIVARIATE	  	  ANALYSIS	  
BASELINE	  CHARACTERISTIC	  	   	   HR	   	   95%	  CI	  	   p	   	   	   	   HR	   	   	   95%	  CI	  	   	   p	  
AGE                1.03             1.01-1.05   0.015                1.02                       0.998-1.04                           0.082 
MALES                               0.796                        0.395-1.60           0.522    -   -                - 
Clinical features 
DURATION OF SYMPTOMS             1.00              0.99-1.01               0.620    -                   -                  - 
SYSTOLIC BLOOD PRESSURE             0.978              0.951-1.00   0.088    -   -                - 
DIASTOLIC BLOOD PRESSURE             0.965              0.94-0.995   0.022                 0.96             0.93-0.99               0.013 
PULSE PRESSURE                             1.01                0.98-1.04               0.524    -                                 -                                             - 
MEAN ARTERIAL PRESSURE                      0.95                           0.92-0.98        0.04    -                                  -                                -  
PULSE RATE               1.01               0.99-1.02              0.483                      -                                              -                                             - 
ATRIAL FIBRILLATION                                1.49                           0.627-3.52               0.368     -                                              -                                              - 
TAMPONADE ON ADMISSION                    3.05                           1.49-6.27                 0.002                   2.44             1.08-5.54              0.033 
Laboratory findings 
CD4+ <200              0.73                           0.308 –1.95          0.442        -      -     - 
CD4+ >200              0.49              0.133-1.77              0.272    -      -     - 
HIV               1.20                      0.677-2.14              0.527    -                    -                     - 
ADA               0.99              0.99-1.01                 0.392    -                    -                                               -               
GLOBULIN (n=85)              0.99              0.95-1.04                0.826    -                    -                     - 
TB ELSEWHERE                                             1.24                           0.49-3.15               0.654                 -                                            -                                                 -             




Predictors of mortality 
From the univariate analysis, four variables which include age, diastolic BP, mean arterial 
pressure and the presence of tamponade on admission were significantly associated with 
mortality; a one year increase in age was associated with a 3% increase in the relative hazard 
of mortality (p = 0.015); a one mmHg rise in diastolic BP is associated with a 4% reduced 
hazard in mortality,(p = 0.022) ; a one mmHg rise in mean arterial pressure is associated with 
a 5% reduced relative hazard of mortality,(p = 0.04); and who were admitted in cardiac 
tamponade had a 3.05 times increased relative hazard of mortality when compared to those 
admitted without tamponade (p =  0.002). 
 
The multivariate analysis obtained after adjusting for age, diastolic BP and tamponade on 
admission was interpreted as follows: 
A one year increase in age is associated with 2% increased relative hazard of mortality (95% 
CI:  0.998 - 1.04). The results are not statistically significant at p = 0.082.       
Similarly every mmHg rise in diastolic pressure is associated with a 4% reduced relative 
hazard of mortality (95% CI:  0.932 - 0.998). The results are statistically significant at p = 
0.013.    
Those with cardiac tamponade on admission had a 2.44 times increased relative hazard of 
mortality when compared to those admitted without tamponade. (95% CI:  1.08 - 5.54). The 
results are statistically significant at p = 0.033.         





Complications of TB pericarditis 
Over a 6 year follow-up period, 11 (5.7%) of the 192 patients needed recurrent pericardial 
aspirations. The overall incidence rate for recurrent pericardial effusions was 47.1 cases per 
1000 person years.  In those with definite disease the incidence rate was 32.9 cases per 1000 
person years (12.3 - 87.7) ; in those with probable TB pericarditis with TB elsewhere the 
incidence rate was 92.1 cases per 1000 person years (23.04 - 368.4) and in those with 
probable TB pericarditis without TB elsewhere, incidence was 55.5 cases per 1000 person 
years (23.1 - 133.3).Using Definite TB pericarditis as a reference group, when compared to 
probable pericarditis with TB elsewhere and probable pericarditis with no TB elsewhere p 
<0.001 and 0.007, respectively. Incidence was lowest in the group with definite TB 
pericarditis. 
During a follow-up period of 6 years, 30 (15.63%) patients developed constrictive 
pericarditis. The overall incidence rate was 132.2 cases per 1000 person–years (92.45 -     
189.12).In those with definite disease the incidence was 146.6 cases per 1000 person-years 
(91.13 - 235.82); in those with probable TB pericarditis with TB elsewhere the incidence rate 
was 138.5 cases per 1000 person-years (44.7 - 429.44) and in those with probable TB 
pericarditis without TB elsewhere, incidence was 112.04 cases per 1000 person years (60.3 -
208.2). Using Definite TB pericarditis as a reference group, when compared to probable 
pericarditis with TB elsewhere and probable pericarditis with no TB elsewhere p =0.318 and 
p=0.057, respectively. There was no significant difference in incidence of constrictive 
pericarditis between the 3 groups. 
 The overall incidence rate of those needing pericardiectomy was 34.4 cases per 1000 person 
– years (17.2 - 68.8).In those with definite disease the incidence rate was 32.9 cases per 1000 




incidence rate was 46.2 cases per 1000 person-years (6.5 - 327.7) and in those with probable 
TB pericarditis without TB elsewhere, incidence was 33.6 cases per 1000 person years (10.8 - 
104.2). Using Definite TB pericarditis as a reference group, when compared to probable 
pericarditis with TB elsewhere and probable pericarditis with no TB elsewhere p =0.07 and 
0.45, respectively There was no significant difference in incidence of pericardiectomy 
between the 3 groups. 
Discussion 
TB pericarditis is a treatable condition that still causes severe morbidity and mortality. (1)              
In our study M tuberculosis was identified in the pericardial fluid or tissue of 93 (48.4%) of 
the patients thus assigning them as definite TB pericarditis whilst the remaining 99 (51.6%) 
were classified as probable disease of which 79 (41.1%) were classified as probable disease 
with no proof of TB elsewhere (except the heart) and 20 (10.4%)  as probable disease with 
proof of TB elsewhere.  
The patient population had an overall mortality of 36 (18.8%) over the 6 year follow-up 
period. This rate is better than other studies conducted in TB pericarditis in which mortality 
ranged from 17 to 40%. (5) An earlier prospective study on mortality in patients treated for TB 
pericarditis had an overall mortality rate of 26% with mortality as high as 40% in those with 
clinical HIV disease over a 6 month period. (1). An important difference between that study 
and the current one is that only 14.1% of their patients underwent pericardiocentesis, unlike 
the current study in which all patients underwent the procedure. This suggests that 





There was no difference in mortality between those with definite disease, probable disease 
with TB elsewhere or those with probable disease with no TB elsewhere (20.4%, 20.0% and 
16.5% respectively; p = 0.799). It is known that extrapulmonary specimens yield lower 
bacillary loads and are consequently associated with low sensitivities in smear and culture. (6)  
It is hypothesized that bacillary density, whilst not routinely quantified, is higher in those 
with definite as opposed to probable disease, and thus more likely to be associated with a 
higher mortality in the former when both are subjected to similar treatment regimens. (6,7) Our 
study does raise the question as to the clinical utility of the distinctions between probable and 
definite entities as it relates to outcomes in patients with TB pericarditis. 
Our results were in stark contrast to a study carried out in patients with tuberculous 
meningitis, a condition that also poses diagnostic and therapeutic difficulty,  in which 
mortality was higher in patients with proven meningeal tuberculosis as compared to patients 
with probable disease (78% and 38% respectively p-value <0.0001)(7). The results  also 
differed from a study performed in India, in which the 18 month mortality was highest in 
those with  smear positive disease (34.7%) and lowest in those with smear and culture 
negative disease (5%). (8)  The aforementioned studies gave credence to our original 
hypothesis, but our findings suggest that this is not the case in TB pericarditis. 
The main factors that predicted mortality in this population were the presence of cardiac 
tamponade on admission, age and a low diastolic blood pressure prior to pericardiocentesis.  
It could be seen that increasing age was associated with a higher mortality, as confirmed by 
other studies.(1)  It would have been important to determine the co-morbidities and causes of 
death in this group of patients as it is likely that poorer states of physical health in older 




A low diastolic pressure may be part of the physical findings in tamponade, although it may 
exist independently of it. Regardless of whether patients had definite or probable disease, a 
low diastolic blood pressure was a predictor of mortality. This occurred independently of 
systolic blood pressure. The mean arterial pressure was an independent predictor of mortality 
but on adjustment, failed to improve the predictive model. 
 
ADA was also confirmed as a tool for use in making an indirect diagnosis of TB pericarditis.  
(9,10). Although ADA was not important as a predictor for death (p = 0.392), it was significant 
as a marker for distinguishing between definite, probable disease with TB elsewhere and 
probable disease with no TB elsewhere, (p-value 0.025). 
Constrictive pericarditis is known to occur in almost all patients with untreated TB 
pericarditis and in 30% to 50% of those who receive anti-TB treatment within the first 6 
months of therapy.(11,12) Constriction developed in 15% of the patients with an overall 
incidence rate of 132.2 cases per 1000 person–years. The rate is significantly lower than that 
reported by Imazio et al of 31.65 cases per 1000 person-years of the 20 enrolled TB 
pericarditis patients who developed constriction.(13) Consequent to severe constriction, 
pericardiectomy may be performed. In a study by Sagrista –Sauleda et al, 57% of their 
patients developed constriction and all proceeded to undergo pericardiectomy.(14) The overall 
incidence rate of pericardiectomy in our study was lower at 34.4 cases per 1000 person – 
years. The incidence rate of recurrent pericardial effusions needing aspiration was 47.1 cases 
per 1000 person-years rate. The incidence of all complications was lower than expected. It 
must be noted that the status of constriction was determined based on file records, and if the 




In conclusion, survival in patients with TB pericarditis is not influenced by whether the 
disease is definite or probable. This is information is important in resource-limited areas 
where diagnostic facilities are limited. Mortality, however, remains unacceptably high in both 
groups of patients. Prospective studies are needed to determine causes of death despite 




The main limitation of this study was that being a retrospective study, not all results were 
available.  The complications that occurred in patients that were referred back to other 
facilities was difficult to ascertain in the majority of patients.	  
Finally, Misclassification of patients with TB elsewhere as only TB pericarditis may have 
occurred if TB elsewhere not looked for or recorded by the examining physician as most 
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APPENDIX	  A:	  1.	  Showing	  excluded	  participants	  
	  




















     
Age (years), median (IQR) 




Duration* (days), median (IQR) 
Pulse (bpm), median (IQR) 
 
 
 Systolic BP, median (IQR) 
 Diastolic BP, median (IQR) 
 Pulse pressure, median (IQR) 
 Mean arterial pressure, median (IQR) 
 
 Atrial Fibrillation, n (%) 




 ADA (IU/L) median (IQR) 
 Globulin (gm/l), median (IQR) 
 
Tested for HIV 
    HIV positive 
    HIV negative 
  
CD4+ count, n (%) 
       <  200 




Follow up in weeks, n (IQR) 
 
*Duration of symptoms before admission 




























20  (32.3)                  
7  (11.3) 




























1  (8.33) 
 
 
7  (43.8)                     
5  (31.25) 





































































     
     
Age	  in	  years;	  duration	  of	  symptoms	  in	  days;	  pulse	  in	  beats	  per	  minute;	  adenosine	  deaminase	  in	  
IU/l	  ;	  globulin	  in	  g/l;	  CD4+	  in	  ;	  blood	  pressure	  in	  mmHg	  ;	  showing	  number	  (n)	  and	  percentage	  of	  
those	  with	  atrial	  fibrillation,	  HIV	  and	  previous	  TB	  and	  also	  showing	  the	  sex	  distribution	  by	  
percentage	  in	  the	  groups	  explored.  IQR	  –interquartile	  range 
(Table 3) summarises the baseline characteristics of the excluded participants. A total of 157 




having probable disease with TB proven elsewhere in the body and 50.3% as probable 
disease with no TB elsewhere in the body. 
When the included and excluded participants were compared by using the p-values of the 
baseline characteristics comparing, the only differences noted were that the there was no 
difference in globulin levels in the excluded group, while the levels were different in the 
included group. There was also no difference in age in the excluded participants whilst the 
included ones showed a difference in age between the three groups based on p-values to 
















































































































The table above describes characteristics in 214 patients who had fairly complete data. The 
greatest determinant for selecting the included patients from the above cohort was the 
presence of a diagnosis for TB elsewhere as this helped determine the groups of analysis. 
There was no missing data for baseline age, gender and duration of symptoms prior to 
admission in 214 patients. In 27 (12.6%) patients, there was no recorded history of 
tuberculosis, and in 51 there was no documentation of TB in another part of the body. 
In 4 (1.96%) patients, there was no recorded blood pressure or pulse prior to 




of the presence or absence of atrial fibrillation. In 10 (4.7%) patients, there was no record of 
tamponade or insufficient information to classify them as having tamponade or not. 
There was no information on ADA for 29 (13.6%) patients. This was due either to 
insufficient specimen samples and/or hemolysis in collected pericardial specimens. Similarly 
for globulin, there was missing data nearly half the patients (55%); this was due to the 
investigation not being routinely requested for patients who were being referred to the GSH 
purely for pericardiocentesis. 
Of the missing HIV data, in 7 out of the 13 patients who status was not known, refusal to 
grant consent was recorded as the reason for not having a test result, whilst in the remainder 
no mention was found of status.  
The preliminary data exploration which looked at Wilcoxon sum rank tests, chi-squared and 
Fischer’s tests used the available data as is. For the Cox Proportional Hazards regression, data 
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